Juniper Networks and TIM Sign Agreement to Drive Telco Cloud Evolution
Memorandum of Understanding Outlines Research and Development of Software-Defined Networking and Open Optical Systems to Enhance End-User Digital Experience
ROME and SUNNYVALE, Calif., Feb. 01, 2018 (GLOBE NEWSWIRE) -- Juniper Networks, an industry leader in automated, scalable and secure networks, and TIM have initiated a joint agreement to collaborate on the research and development of an innovative cloud-oriented network infrastructure. The parties plan to explore the viability of a next-generation platform based on automation, virtualization and open interfaces in support of a wide range of high-performance, secure digital services. In particular, TIM is focused on the evolution of its FutureNET and ultrabroadband customer network platforms to ensure they are fit for purpose as IoT and 5G requirements become more relevant over the next five years.
The Memorandum of Understanding (MoU) between the two organizations will facilitate thorough experimentation and testing of new networking techniques in a drive to enhance performance, reliability and security. The MoU is also intended to foster greater levels of partnership with a comprehensive ecosystem of technology providers and industry forums, enabling rich functionality, ongoing innovation and best practice.
"TIM's goal is to accelerate its evolution towards the network of the future. Our vision is towards a more automated, interconnected and agile network that reacts more easily to customer demands. Through the development of Software-Defined Networking and open optical systems, TIM will be able to develop a host of software components that can be activated where and when needed, based on customer needs. We have chosen to work with Juniper Networks via the research and innovation embodied in this MoU because the company shares our vision of transformation through network openness, virtualization and simplification to drive a superior digital customer experience."
Enrico Bagnasco, Head of Innovation at TIM
"Juniper believes that simplicity in both network design and operation has to become a core value for the networking industry and we welcome the opportunity to work with a forward-thinking operator such as TIM to help deliver effective solutions for the challenges presented by trends such as IoT, security, 5G and big data. We are committed to sharing expertise, projects, laboratories and resources to design, experiment and implement the technologies to foster the digital transformation that will enable the next-generation service offerings to TIM's customers across Italy."
Tom Ruban, Chief Technical Officer EMEA at Juniper Networks
About Juniper Networks
Juniper Networks simplifies the complexities of networking with products, solutions and services in the cloud era to transform the way we connect, work and live. We remove the traditional constraints of networking to enable our customers and partners to deliver automated, scalable and secure networks that connect the world. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on Twitter and Facebook.
TIM is Italy's leading telco operator and ICT group. Its offer includes landline and mobile voice services, data, premium digital contents - films, music, games, e-books - and services for private customers and businesses.
Keywords at TIM are: top customer experience; smart, flexible and scalable bundles; convergence; a UBB-centric customer base supported by extensive new generation networks (at November 2017 73 percent of Italian household reached with fibre; 98 percent of population covered with 4G).
TIM controls TIM Brasil, a major player in the local market.
Juniper Networks, the Juniper Networks logo, Juniper and Junos are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.
Media Relations Juniper Networks:
+44 (0) 1372 385 611
TIM Press Office:
+39 06 3688 2610
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Juniper Systems Limited via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Resverlogix Provides Unrestricted Educational Grant for Epigenetic Symposium at International Renal Congress25.5.2018 07:45 | Pressmeddelande
CALGARY, Alberta, May 24, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that on Friday, May 25, 2018, at the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress in Copenhagen, Denmark, the Company is supporting a symposium titled: "Epigenetics in CKD & CVD: A potential breakthrough therapy?" The symposium highlights the role of epigenetics and BET-inhibition in chronic kidney disease and cardiovascular disease, especially in patients with diabetes mellitus, and the significant unmet need that still exists in this patient population. The symposium is co-chaired by Vincent M. Brandenburg, MD - Nephrologist, Aachen, Germany and Kamyar Kalantar-Zadeh, MD - UC Irvine School of Medicine, Irvine, CA, USA, both leading scientists also serving as advisors to Resverlogix's Renal program. The speakers and agenda are as follows: Introduction Vincent M. Brandenburg, MD - University Hospital of the RWTH
Atico Reports Consolidated Financial Results for the First Quarter of 201824.5.2018 22:30 | Pressmeddelande
(All amounts expressed in US dollars, unless otherwise stated) VANCOUVER, British Columbia, May 24, 2018 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the "Company" or "Atico") (TSX.V:ATY) (OTC:ATCMF) today announced its financial results for the three months ended March 31, 2018, posting a net income of $0.4 million. Fernando E. Ganoza, CEO and Director, commented, "The strong production and all-in sustaining cash cost of $1.85 achieved this quarter is not reflected in the financial results as a large concentrate shipment was delayed to the second quarter, along with the revenue associated with those tonnes. The shipping schedule is expected to stabilize during the second quarter, where we will then benefit from the additional shipped concentrate and recognized revenue. We anticipate strong financial results in the next quarter." Mr. Ganoza continued, "Our emphasis will continue to be on further strengthening our balance sheet, improving production costs and most importantly regional
Elemica Reports Double Digit Network Growth and Announces New Product Innovations in First Quarter 201824.5.2018 18:18 | Pressmeddelande
Helping Process Manufacturers Undergo Digital Transformation Leads to Introduction of New Transformative Solutions WAYNE, Pa., May 24, 2018 (GLOBE NEWSWIRE) -- Elemica, the leading Digital Supply Network for process manufacturing industries, announces the company's first quarter results of 2018 highlighting substantial network growth and new product innovations. The Elemica Digital Supply Network had significant network expansion in the first quarter with traffic growing 10 percent year-over-year in Q1. Shipment traffic grew substantially based on new product expansions of Elemica Trace. "Elemica's growth can be attributed to our clients needing our expertise and technology to undergo a Digital Transformation that connects, automates, anticipates and transforms their enterprise for their business growth initiatives," said John Blyzinskyj, CEO of Elemica. "Our digital supply network enables businesses to grow their top and bottom lines, mitigate risk and improve customer satisfaction ac
Luxembourg Announced as SNOMED International's Newest Member24.5.2018 15:16 | Pressmeddelande
London, United Kingdom, May 24, 2018 (GLOBE NEWSWIRE) -- SNOMED International and Agence eSanté Luxembourg are pleased to announce that Luxembourg has joined the organization as its thirty-second Member. Luxembourg, one of the leading nations in the area of information and communication technology, has set the development of eHealth technologies as a high priority. Agence eSanté, Luxembourg's national agency for the exchange and sharing of medical data, has set an overall mission to facilitate clinical information exchange both within Luxembourg and across other international actors. To work towards this reality, the agency has taken part in discussions about standardization across Europe, a contributing building block achieved with its membership in SNOMED International. With their membership, Agence eSanté has committed their support for the use of structured clinical terminology. When applied to the health sector, interoperability ensures that information systems, and through them h
SEMAFO Signs Underground Mining Services Contract with AUMS24.5.2018 14:00 | Pressmeddelande
MONTREAL, May 24, 2018 (GLOBE NEWSWIRE) -- SEMAFO Inc. (TSX:SMF) (OMX:SMF) reports that it has signed a mining services contract with African Underground Mining Services ("AUMS") to provide turnkey mining services for Siou underground. AUMS is a well-known and reputable mining contractor with underground experience in Burkina Faso and across Africa. Under the mining services contract, AUMS will be responsible for supplying the mining fleet and a skilled labour force for Siou underground in addition to ensuring development, production and auxiliary services. SEMAFO will provide technical services including geology and engineering as well as leveraging the existing surface infrastructure at Mana. The mining services contract has a term of 70 months. The economic terms of the mining services contract are consistent with the economics presented in the Mana pre-feasibility study filed March 29, 2018 on SEDAR. Preparatory work has already commenced on Siou underground with full project deplo
Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors24.5.2018 13:00 | Pressmeddelande
- IND Accepted in April by the U.S. FDA for MCLA-158 - UTRECHT, The Netherlands, May 24, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the first patient has been dosed in a Phase 1, first-in human clinical trial of MCLA-158 in patients with solid tumors with an initial focus on metastatic colorectal cancer. The trial will be conducted in Europe, where several Clinical Trial Applications (CTAs) have been approved to date. The Company also announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for MCLA-158, which was accepted by the FDA in April 2018. With this acceptance, Merus plans to open additional sites for this trial in the United States. MCLA-158 is designed to bind to cancer stem cells expressing leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5) and epidermal grow
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum